Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: Prevalence and clinical characteristics
Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: Prevalence and clinical characteristics
复制标题
DOI：
10.1016/j.eplepsyres.2015.05.008
复制
发表时间：
2015-09-01
影响因子：
2.2
通讯作者：
Sander, Josemir W.
中科院分区：
文献类型：
--
作者：
Keezer, Mark R.;Novy, Jan;Sander, Josemir W.
背景：关于糖尿病和癫痫之间的潜在联系的报道一直不一致。方法：我们连续检查了2016名在三级医学中心住院的耐药癫痫患者。结果：我们确定了20名1型糖尿病(T1 DM)患者；每1000名患者中有9.9例(95%可信区间：6.4，15.3)。与已公布的T1 DM在普通人群中的患病率估计相比，这意味着增加了两倍多。在80%的个体中，T1 DM的发病先于癫痫发作，中位数为1.5年。与患有2型糖尿病或不患有糖尿病的人相比，患有T1糖尿病的人更有可能患有不明原因/不明原因的癫痫(85%比35%和49%，p=0.045)。所有T1 DM患者都有局灶性癫痫，其中大部分起源于颞叶，尽管没有证据表明这一比例与非T1 DM患者有任何不同(p>；0.999)。结论：T1 DM在耐药癫痫患者中的患病率似乎增加，并与不明原因/不明原因癫痫有关。这些发现可能具有病理生理学意义，特别是在抗谷氨酸脱羧酶抗体的背景下。(C)2015爱思唯尔B.V.保留所有权利。
Background: There have been inconsistent reports on the potential association between diabetes mellitus and epilepsy.Methods: We examined a consecutive cohort of 2016 people with pharmacoresistant epilepsy admitted to a tertiary medical centre.Results: We identified 20 individuals with type 1 diabetes mellitus (T1DM); a point prevalence of 9.9 (95% CI: 6.4, 15.3) cases per 1000 individuals. This represents a more than two-fold increase relative to published prevalence estimates of T1DM in the general population. The onset of T1DM preceded that of epilepsy in 80% of individuals, by a median of 1.5 years. Individuals with T1DM were significantly more likely to have cryptogenic/unknown epilepsy relative to those with type 2 diabetes mellitus or without diabetes (85% versus 35% and 49%, p = 0.045). All individuals with T1DM had focal epilepsy, the majority of which were temporal lobe in origin, although there was no evidence that this proportion was any different from those without T1DM (p > 0.999).Conclusions: The prevalence of T1DM appears to be increased in people with pharmacoresistant epilepsy and is associated with cryptogenic/unknown epilepsy. These findings may have pathophysiological implications, especially in the context of anti-glutamic acid decarboxylase antibodies. (C) 2015 Elsevier B.V. All rights reserved.